NCT03460782

An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas

• Status: No Longer Available
• Phase: —
• Study type: Expanded Access
• Enrollment: —
• Sponsor: Center Trials & Treatment · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: —

Summary

IPILIMUMAB Extended Access Program for patients who received chemotherapy and / or radiation therapy before the protocol, before or after the operation.

Detailed description

It is not yet known which protocols are a better treatment for glioblastoma or glioma. The ipilimumab extended-access program for patients who received previous chemotherapy and / or radiation therapy by protocol, before ((for non-operable cases) or after the operation. Monoclonal antibodies of CTLA-4, such as ipilimumab, may block tumor growth in different ways by targeting certain cells and activating the patient's immune system to fight the disease.

Conditions

• Glioblastoma
• Glioma of Brain

Interventions

Type	Name	Description
BIOLOGICAL	Ipilimumab	Each patient receives Ipilimumab in regimen and dose according to the official manufacturer's instructions (IV 1 mg / kg every 6 weeks for maximum of 4 doses). Participation of the patient in the program must necessarily be agreed with the current treatment and contain a written agreement with the attending physician. This program is not covered by health insurance. For patients in the postoperative period to provide a mandatory conclusion of histology and molecular-genetic for the identified mutations and the type of tumor.

Timeline

• First posted: 2018-03-09
• Last updated: 2019-11-08

Locations

11 sites across 8 countries: Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Romania, Russia, Serbia, Switzerland